Cell And Gene Therapy Third-Party Logistics Market Forecast From USD 1.81 Billion In 2025 To USD 16.95 Billion By 2035 Drives By Personalized Medicine Growth

2026-01-07 10:02:11

(MENAFN- GlobeNewsWire - Nasdaq) The global cell and gene therapy third-party logistics market size was valued at USD 1.81 billion in 2025 and is predicted to hit around USD 16.95 billion by 2035, rising at a 25.05% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

Ottawa, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The global cell and gene therapy third-party logistics market size

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @

Key Takeaways

The cell and gene therapy third-party logistics sector pushed the market to USD 2.27 billion by 2026.
Long-term projections show a USD 16.95 billion valuation by 2035.
Growth is expected at a steady CAGR of 25.05% in between 2026 to 2035.
North America was dominant in the market in 2024.
Asia Pacific is expected to be the fastest-growing region during 2025-2034.
By type, the clinical segment led the cell and gene therapy third-party logistics market in 2024.
By type, the commercial segment is expected to witness rapid expansion in the upcoming years.
By product, the cell therapies segment dominated the market in 2024.
By product, the gene therapies segment is expected to grow at a rapid CAGR in the studied years.
By temperature range, the ambient storage segment held the largest share of the market in 2024.
By temperature range, the refrigerated storage segment is expected to grow fastest during 2025-2034.
By end-use, the biopharmaceutical companies segment was dominant in the market in 2024.
By end-use, the CDMOs/CMOs segment is expected to be the fastest-growing in the coming years.

What are the Emerging Developments in the Cell and Gene Therapy Third-Party Logistics?

The cell and gene therapy third-party logistics market covers many specialized companies that handle the highly complex, patient-centric supply chain for delicate, live biological therapies clinical trials/approvals logistics for life sciences

Become a valued research partner with us -

What are the Key Drivers in the Cell and Gene Therapy Third-Party Logistics Market?

Along with the rising demand for precision medicine, the market is propelled by progressing CGT research and regulatory approvals biopharma companies

Trends in the Cell and Gene Therapy Third-Party Logistics Market

In December 2025, SCTbio and Fortrea made a strategic collaboration agreement between the two companies to simplify development, accelerate timelines and execute advanced therapies to patients rapidly.
In December 2025, ENCell signed a memorandum of understanding (MOU) with Cell Therapies, CGT CDMO, to widen access to CGT development and manufacturing in the Asia-Pacific (APAC) region.

What is the Developing Challenge in the Market?

Specifically, higher temperature/time sensitivity, complex autologous supply chains (patient-specific), stricter regulatory obstacles, needing specialised 3PLs for cold chain, real-time tracking, and customs are creating major barriers in the cell and gene therapy third-party logistics market.

Regional Analysis

Why did North America Dominate the Market in 2024?

By capturing a dominant share, North America led the market in 2024. A prominent catalyst is strict guidelines from the FDA and adherence to Good Distribution Practices (GDP) mandate advanced storage and transportation protocols. Alongside, the region is encouraging the progression of cold chain capabilities, such as UPS Healthcare, which expanded its cold chain infrastructure in Louisville, Kentucky, with the emergence of innovative freezer farm and latest temperature monitoring technologies to assist the distribution of temperature-sensitive biologics and vaccines.

For instance,

In October 2025, Frontier Scientific Solutions, a contract service organization (CSO), and Air Transport Services Group partnered to accelerate the delivery process surrounding temperature-controlled pharmaceuticals.

Why did the Asia Pacific Grow Significantly in the Market in 2024?

In the coming era, the Asia Pacific is anticipated to expand rapidly in the cell and gene therapy third-party logistics market. Ongoing biotech investments, particularly in China, Japan, India, and a rise in the pipeline of therapies, are increasingly demanding specialised cold-chain logistics and stringent quality control. Whereas China is immensely investing in temperature-controlled warehouses, ultra-low temperature storage, like -70°C and -196°C for biosamples and products, and express cold-chain transportation infrastructure to complete the increasing demand and strict government regulations.

For instance,

In June 2025, Porton Advanced Solutions collaborated with Egypt-based EVA Pharma to develop and boost chimeric antigen receptor (CAR) T-cell therapy development and manufacturing capabilities, using EVA Pharma's facilities in the Middle East & Africa.

Get the latest insights on life science industry segmentation with our Annual Membership:

Government Initiatives in the Respective Market in 2024-2025

Medical Product Supply Chain Resilience (HHS)	Exploring a 2025–2028 Action Plan, especially focusing on addressing shortages and enhancing the resilience of medical product supply chains, mainly for pharmaceuticals and advanced biologics.
BioSecure Act of 2024	This is emphasized restrict U.S. collaboration with specific Chinese biotech firms over genomic data issues, incentivizing a movement toward domestic and allied 3PL and CDMO partners.
Spanish MIA License Progression	In 2024, Spain's medicine agency authorised Alcura (Cencora) a Manufacturing and Importation Authorization (MIA) license, to allow specialized import and storage services for commercial CGT products in the region.

Segmental Insights

By type analysis

How did the Clinical Segment Lead the Market in 2024?

The clinical segment captured a major share of the cell and gene therapy third-party logistics market in 2024. Raised emphasis on patient-centric supply chains, handling limitations, and the expansion of cell/gene therapies for oncology, elevating the ned for strong networks for sample collection, distribution, and delivery. Specifically, 3PLs are providing more united services, from patient ID to data collection, assisting both autologous (circular) and allogeneic (linear) supply chains.

However, the commercial segment is anticipated to expand rapidly. Continuous rising demand for precision therapies, with spurring biotech R&D, and ongoing breakthroughs in cold chain, real-time monitoring, and tracking systems are bolstering the scalable, global distribution networks. Additionally, firms are leveraging scaling manufacturing by using AI, automation, and decentralized production for better access. Additionally, they are promoting innovative delivery systems like lipid nanoparticles

By product analysis

Which Product Dominated the Cell and Gene Therapy Third-Party Logistics Market in 2024?

The cell therapies segment held the biggest share of the market in 2024. Specifically, autologous (patient's own cells) and allogeneic therapies need intricate, "vein-to-vein" supply chains with stricter temperature control. Currently, many companies are investing in cryogenic shippers, ultra-low temperature freezers, and specialized handling, with the development of logistics networks with facilities in the US & EU to support global access.

Furthermore, the gene therapies segment is predicted to witness rapid expansion. The globe is stepping towards patient-specific treatments for cancer, genetic disorders, and neurological conditions, with persistent innovations in viral vectors, such as CRISPR-based delivery and advanced cold chain tech (cryo-storage, ambient), supporting prospective gene therapy enhancement

By temperature range analysis

Why did the Ambient Storage Segment Dominate the Market in 2024?

In 2024, the ambient storage segment registered dominance in the cell and gene therapy third-party logistics market. Diverse gene therapies and advanced biologics are becoming more stable

On the other hand, the refrigerated storage segment is anticipated to register the fastest growth. Prominently needed for live cells/viral vectors, which are highly temperature-sensitive, and require refrigerated (2-8°C) or cryogenic storage. For example, PROVENGE (sipuleucel-T), an autologous immunotherapy for prostate cancer, can be kept in the infusion bag at 2-8°C until infusion.

By end-use analysis

What Made the Biopharmaceutical Companies Segment Dominant the Market in 2024?

The biopharmaceutical companies segment held a major share of the market in 2024. Mainly, they are focusing on exploring integrated solutions to cover packaging

However, the CDMOs/CMOs segment is estimated to expand rapidly. Lonza, Thermo Fisher Scientific (Patheon), Catalent, Novartis (Cell & Gene Therapies), are providing CGT manufacturing, viral vector services, and logistics for autologous (patient-specific) & allogeneic therapies. Also, they are putting robust efforts into cell therapy development, manufacturing (CAR-T), and integrated supply chain solutions.

You can place an order or ask any questions, please feel free to contact us at ...

Key Developments in the Cell and Gene Therapy Third-Party Logistics Market

In October 2025, Orsini, a leader in rare disease pharmacy solutions, launched its integrated specialty pharmacy and third-party logistics (3PL) solution, powered by the company's new Columbus, Ohio facility.
In August 2025, Bionova Scientific, a full-service biologics contract development and manufacturing organisation (CDMO) and subsidiary of Asahi Kasei, unveiled a 10,000 square-foot plasmid DNA (pDNA) development and production facility in The Woodlands, Texas.
In August 2025, Celcius Logistics launched Celcius+, a specialised logistics vertical that emphasised only the pharmaceutical supply chain.
In January 2025, Cryoport, Inc., launched its Cryoport Express Cryogenic HV3 Shipping System ("HV3"), its newest comprehensive portfolio for transporting lifesaving biologics and temperature-sensitive therapies.

Browse More Insights of Towards Healthcare:

The global cell and gene therapy CRO market

The global cell and gene overexpression service market

The global cell and gene therapy thawing equipment market

The global cell and gene therapy isolator market

The global cell and gene therapy drug delivery devices market

The global cell and gene supply chain solutions market

The cell and gene therapy infrastructure market

The global cell and gene therapy tools and reagents market

The global cell and gene therapy manufacturing QC market

The global cell and gene therapy (CGT) pharmaceuticals market

Cell and Gene Therapy Third-Party Logistics Market Key Players List

Cencora Corporation
Cardinal Health
McKesson Corporation
EVERSANA
Knipper Health
Arvato SE
DHL
FedEx
Kuehne + Nagel
United Parcel Service of America, Inc.

Segments Covered in the Report

By Type

Clinical
Commercial

By Product

Cell Therapies
Gene Therapies

By Temperature Range

Ambient Storage
Refrigerated Storage
Ultra-Low Temperature Storage
Cryogenic Storage

By Therapeutic Area

Oncology
Neurology
Cardiovascular Diseases
Ophthalmology
Infectious Diseases
Others

By End-use

Biopharmaceutical Companies
CDMOs/CMOs
Others

By Region

North America

U.S.
Canada

Asia Pacific

China
Japan
India
South Korea
Thailand

Europe

Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway

Latin America

Brazil
Mexico
Argentina

Middle East and Africa (MEA)

South Africa
UAE
Saudi Arabia
Kuwait

Immediate Delivery Available | Buy This Premium Research @

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research

You can place an order or ask any questions, please feel free to contact us at ...

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web:

Our Trusted Data Partners

Precedence Research | Towards Packaging | Towards Food and Beverages | Towards Chemical and Materials | Towards Dental | Towards EV Solutions | Healthcare Webwire

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

MENAFN07012026004107003653ID1110568072

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.